Heavily encapsulated Klebsiella pneumoniae (serotypes 1 and 2) was cultured in the presence of sodium salicylate. The addition of salicylate (2 to 30 ,ug/ml) progressively decreased the amount of capsular polysaccharide produced by all strains without significantly inhibiting cell growth. Further addition of salicylate (50 to 200 ,ug/ml) was progressively inhibitory to cell growth and decreased the production of polysaccharide only slightly. The optimal concentration of salicylate that could reduce the polysaccharide production of heavily encapsulated, virulent strains by 50% or more was 30 ,ug/ml. Mutants of these bacteria that produced less capsule were affected by salicylate to a lesser degree. All concentrations of salicylate tested were physiologically achievable in humans and within the therapeutic range of aspirin. The addition of calcium and magnesium partially reversed the effects of salicylate on polysaccharide production. Chelating agents, particularly EGTA [ethylene-bis(oxyethylenenitrile)tetraacetic acid], reduced capsule production as salicylate did. Thus, the chelation of calcium and magnesium by salicylate could account, at least in part, for the reduction of capsule. Optical density measurements allowed for rapid monitoring of capsule production in various culture media because a large part of culture turbidity was apparently due to the capsule. Decreased production of the primary K. pneumoniae virulence factor with salicylate may have therapeutic potential.
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Klebsiella pneumoniae is characteristically surrounded by a polysaccharide layer, referred to as a capsule. The capsule shields these organisms from host defenses and is an important virulence factor (21) . Typically, the larger the capsule produced, the more pathogenic the strain (8, 9, 11). Reduction or loss of capsular polysaccharide (CPS) by mutation results in increased susceptibility to phagocytosis and loss of virulence (8, 9, 24, 27) . Virulent strains also release into the culture medium large quantities of cell-free, extracellular CPS (9), which is actually an aggregate of CPS and lipopolysaccharide and is another important virulence factor (2, 9, 20, 25, 28) . Together, cell-associated and cell-free CPSs produce biofilms in vivo that are refractory to host defenses and to antibiotic therapy (5) .
Chemotherapeutic agents that reduce the production of CPS may provide a unique adjunct to therapy against infections caused by encapsulated bacteria. Antimicrobial agents with activity against K. pneumoniae may be more effective in the presence of less capsule. Moreover, the reduction of CPS may enable host defenses to clear encapsulated organisms more effectively. However, reducing capsule size by promoting the release of CPS from the bacterial cell, as some antibiotics have been shown to do, may do more damage than good (4) . Only by reducing CPS production can these agents be of benefit in vivo. In this communication, a variety of agents were tested for their abilities to reduce CPS production by serotype 1 and 2 K. pneumoniae.
MATERIALS AND METHODS
Bacteria and culture methods. Bacteria employed in these studies were serotype 1 (ATCC 8047) and serotype 2 (CDC 2-70) K. pneumoniae and their isogenic variants with regard to CPS production. The chemically defined medium designed for maximum capsule production was similar to that of Duguid and Wilkinson (10) The CPS was allowed to precipitate at 4°C for 30 min. The samples were again centrifuged for 5 min, the supernatants were thoroughly decanted, and the precipitates were allowed to dry. The samples were allowed to redissolve overnight in 250 ,ul of 100 mM HCl and were assayed for CPS by measuring uronic acid (3) and for lipopolysaccharide by measuring 2-keto-3-deoxyoctulosonic acid (14) . Estimations of extracellular CPS were performed on ethanol-precipitated culture supernatants. Packed-cell volume (PCV) was determined in triplicate by centrifuging 1 ml of culture at 14,000 rpm for 5 min in the microcentrifuge and measuring the volume of pelleted cells. Capsule size was measured by light microscopy with an ocular micrometer, using India ink as a negative stain. Capsule size is expressed as the average transverse diameter (TD) of 100 randomly selected cells (8) .
RESULTS
Bacterial variants in CPS production were isolated on the basis of colony morphology on agar media (9). From two copious capsule producers, variants that produced 10 to 30% of the CPS produced by the original strains were isolated. Variants in CPS production within each strain were shown to be identical with regard to biotyping on API 20E strips (Analytab Products, Plainview, N.Y.) and by their plasmid DNA profiles on agarose gels (7). For purposes of convenience, small capsule (SC) producers were labeled SC-1 and SC-2 for serotypes 1 and 2, respectively. Large capsule (LC) producers were labeled LC-1 and LC-2 accordingly.
The chemically defined medium of Duguid and Wilkinson for CPS production (10) supported the growth of some, but not all, of the strains employed. Levels of all nutrients contained in the medium were adjusted to ensure adequate growth, to maximize CPS production, and not to exceed the optical density (OD) limits of the Abbott MS-2. The addition of 0.1% Casamino Acids as the sole nitrogen source was suitable for this purpose. Moreover, the medium retained the limiting nitrogen balance necessary for maximum CPS production (10) .
The addition of SAL to the growth medium affected the production of CPS from LC-1 and LC-2 profoundly. Levels of SAL as low as 10 ,ug/ml decreased the amount of CPS produced from LC-2 by over 40% (Fig. 1) . At 30 ,ug of SAL per ml, CPS was reduced by nearly 60%. Further increases in SAL had diminishing effects on CPS production. At 350 jig of SAL per ml, CPS was reduced by approximately 70% (data not shown). The effect of SAL on strain LC-1 was even more pronounced (Fig. 2) , with a reduction of CPS by one-third at 2 ,ug/ml (14 ,uM) and by nearly two-thirds at 10 p.g/ml (72 ,uM). Again, increasing SAL beyond this point had little effect on CPS production. Strain SC-1 was also affected by the addition of SAL, but the decrease in CPS was not as pronounced (Fig. 2) . Strain SC-2 also showed a less pronounced reduction of CPS in the presence of 10 ,ug of SAL per ml (from 40.4 to 34.7 ng/106 CFU). There were no notable or significant differences in the amounts of Zwittergent-extracted lipopolysaccharide found among the samples (data not shown).
Several associated aspects of capsule production were measured to support these findings. When SAL was added to medium at up to 100 ,ug/ml, major changes were seen in the OD of culture, TD, PCV, and log CFU per milliliter. ,ug/ml (----) or 30 ,ug/ml (---.) and in the absence of SAL (-).
Samples were removed at intervals, and the CPS was extracted and measured for its uronic acid content (3). Error bars represent 1 standard deviation from the mean.
tration, little or no change in these parameters was seen, except for a decrease in cell viability. In the presence of SAL, the OD, TD, and PCV of LC strains were similar to those of untreated SC strains.
Changes in culture turbidity and cell viability for strain LC-2 are illustrated in Fig. 3 tion. Figure 4 shows the comparative abilities of these agents to reduce LC-2 CPS production per cell. The effect of EGTA on CPS was notable and at higher doses was similar to that of SAL. EDTA (1 mM) was even more effective at reducing CPS than was SAL or EGTA, though cell viability in EDTA-treated cultures dropped precipitously at these high levels. However, at lower concentrations, SAL was more effective than EGTA or EDTA at reducing the production of CPS. At 0.2 mM chelating agent, SAL was significantly more effective at reducing CPS than was EGTA (P c 0.025) or EDTA (P c 0.0005).
Variations in the divalent cation concentration of the culture medium were seen to modulate the reduction of CPS by SAL. These experiments, conducted on strain LC-2, are summarized in Table 2 . When calcium was lowered 100-fold (from 5.44 to 0.054 mg/liter), the effect of SAL on CPS production was even more pronounced. SAL at 2 ,ug/ml effected a 20% reduction in CPS at the lower calcium level, compared with virtually no CPS reduction at the higher calcium level, regardless of the magnesium concentration.
At higher levels of SAL (50 jig/ml), lowering the magnesium concentration 10-fold, from 23.9 to 2.39 mg/liter, effected a 14 to 18% increase in CPS reduction. Variation in the ferric or zinc ion concentration (from 1 to 10 mg/liter) had little effect on the reduction of CPS by SAL (data not shown). (18) . The K. pneumoniae strains employed in this study were either in the O1:K1 or O1:K2 serogroup, and all were shown to be susceptible to the effects of SAL. At the optimal concentration of SAL (30 ,ug/ml), several characteristic changes in the K. pneumoniae cultures took place. The addition of SAL to culture media significantly reduced the quantity of CPS produced by these bacteria. TD and PCV were also reduced proportionally. The decrease in TD or PCV was not due to release of CPS into the culture medium, since quantitation of CPS was determined on the entire culture, not just on the cell pellet. Moreover, quantitation of CPS in ethanol-precipitated culture supernatants showed no increase in cell-free CPS.
Cell death could not account for the decrease in CPS or PCV, since viable cell numbers remained unchanged at SAL levels optimal for reducing CPS. Moreover, SAL did not affect the lag times before logarithmic growth. The antimicrobial effects of SAL were minor and were not observed until its effect on CPS production diminished. Thus, SAL exerts its effect on CPS production at subinhibitory levels. These levels of SAL are also within the therapeutic range measured in human serum after ingestion of aspirin. Toxic levels of SAL in serum in humans begin at about 200 to 350 jig/ml (15) .
SAL had a pronounced effect on the elaboration of CPS regardless of the culture medium employed. The reduction of CPS by SAL held true even in medium as complex as serum. However, when the levels of magnesium and calcium in our culture medium were varied, the effects of SAL were altered considerably. Low levels of calcium enabled smaller doses of SAL to be more effective, while low levels of magnesium allowed larger doses of SAL to be more effective. These data are further supported by experiments with other chelating agents. Comparatively low levels of EGTA (with a high affinity for calcium) had a greater effect on the production of CPS than did EDTA (with a high affinity for magnesium). At higher concentrations, EDTA had a more profound effect than EGTA on CPS production.
Speculation on the mechanism of CPS reduction must take into account several known properties of SAL. As to its chelating properties, SAL has been identified as the biosynthetic precursor of the aromatic ring in pyochelin (R. Ankenbauer and C. D. Cox, Abstr. Annu. Meet. Am. Soc. Microbiol. 1988, D-117, p. 90), which is an iron-binding siderophore produced by Pseudomonas aeruginosa. Metal ions are known to be cofactors for enzymes directly involved in polysaccharide synthesis (26) . Divalent cations also play an important role in bacterial outer membrane stabilization (16) . Thus, chelating agents may affect CPS production either by modulating enzyme activity or by affecting the functional integrity (i.e., nutrient uptake or translocation) of the outer membrane. SAL can also adsorb to lipid bilayers and increase the negative surface potential of the inner membrane (17) , where the biosynthetic enzymes for CPS are located. These phenomena and their influence on CPS biosynthesis are currently under study in our laboratory.
Two layers of capsule can be observed in electron micrographs of encapsulated K. pneumoniae. The inner layer is dense and perpendicular to the cell surface, while the outer layer consists of a fine network of fibers (1) . SC strains appear not to have this outer layer of capsule and are 4 to 5 log units less virulent than their parent strains to mice or rats (8, 9) . From our observations of these cells under light microscopy, it appears that SAL repressed the production of this outer layer of capsule. Indeed, SAL-treated LC strains could not be distinguished from untreated SC strains by their TD, PCV, or culture turbidity. SAL also reduced the amount of CPS in LC strains to that in untreated SC strains, but its effect diminished thereafter. These data indicate that the increased CPS production in LC as opposed to SC strains, which may be plasmid mediated (19) , is completely inhibitable by SAL. Given that this increased CPS production is necessary to protect bacteria from host defenses, SAL may prove beneficial therapeutically for infections caused by encapsulated bacteria. The in vivo correlates of the SAL effect are currently being tested.
A reduction in CPS produced by heavily encapsulated strains has also been shown to occur in the presence of several cephalosporins (13) . Subinhibitory doses of azlocillin and mezlocillin have also been reported to render K. pneumoniae more susceptible to the antimicrobial action of leukocytes (6) . Perhaps the combined effect of SAL and these antibiotics works additively to reduce CPS production. However, SAL has been shown to repress outer membrane porin synthesis, which results in an increased resistance to several antibiotics that enter gram-negative cells through porin channels (12, 22, 23) . The effect of combined SAL and antibiotics on CPS production and bacterial growth is currently under investigation in our laboratory.
Quantitation of CPS in this study was aided by the use of an improved method for CPS extraction (7) . Without this rapid and simple method, determinations of CPS would have been tedious and imprecise. The effects of agents that alter the production or release of extracellular polysaccharides can now be tested with precision. Moreover, the Abbott MS-2 analysis module facilitated these measurements, not only by allowing multiple tests to be performed simultaneously, but also by monitoring the turbidity of cultures. Since a large part of the culture turbidity was apparently due to the capsule, the Abbott MS-2 was useful as a monitor of capsule formation under defined conditions.
